Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Day One Biopharmaceuticals (DAWN) Net Income towards Common Stockholders (2023 - 2025)

Historic Net Income towards Common Stockholders for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Q3 2025 value amounting to -$19.7 million.

  • Day One Biopharmaceuticals' Net Income towards Common Stockholders fell 15494.42% to -$19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.7 million, marking a year-over-year increase of 2158.68%. This contributed to the annual value of -$204.7 million for FY2024, which is 836.13% down from last year.
  • According to the latest figures from Q3 2025, Day One Biopharmaceuticals' Net Income towards Common Stockholders is -$19.7 million, which was down 15494.42% from -$30.3 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year Net Income towards Common Stockholders high stood at $35.8 million for Q3 2024, and its period low was -$112.4 million during Q2 2024.
  • In the last 3 years, Day One Biopharmaceuticals' Net Income towards Common Stockholders had a median value of -$46.0 million in 2023 and averaged -$43.7 million.
  • In the last 5 years, Day One Biopharmaceuticals' Net Income towards Common Stockholders skyrocketed by 17766.49% in 2024 and then crashed by 15494.42% in 2025.
  • Day One Biopharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at -$54.5 million in 2023, then dropped by 20.61% to -$65.7 million in 2024, then surged by 70.04% to -$19.7 million in 2025.
  • Its last three reported values are -$19.7 million in Q3 2025, -$30.3 million for Q2 2025, and -$36.0 million during Q1 2025.